In Immunotherapy, Approved Biomarkers Pose Many Problems – Medscape
Medscape |
In Immunotherapy, Approved Biomarkers Pose Many Problems
Medscape The US Food and Drug Administration (FDA) recently licensed for the first time use of an immunotherapy solely on the basis of the presence of a biomarker. The labeling was approved just 10 days before the 2017 annual meeting of the American Society of … |
